Heme oxygenase system and hypertension: a comprehensive insight.

Abstract

Hypertension is a complex interplay of interrelated etiologies, and the leading risk factor for many cardiovascular morbidity and mortality worldwide. Cardinal pathophysiological features of hypertension include enhanced vascular inflammation, vascular remodeling, vascular contractility and increased oxidative stress. In response to oxidative, inflammatory or other noxious stimuli, many physiological pathways like the heme oxygenase (HO) system are activated in an attempt to counteract tissue insults. However, the pathophysiological activation of the HO system only results to a transient increase of HO activity that fall below the necessary threshold capable of activating the downstream signaling components of the HO system like the soluble guanylyl cyclase (sGC)/cyclic guanosine monophosphate (cGMP) secondary messenger system. Therefore, a more robust potentiation of the HO system by pharmacological agents such as hemin, heme-arginate, cobalt protoporphyrin or through retroviral HO-1 gene delivery would be needed to surmount the threshold for cytoprotection. The HO system modulates cellular homeostasis. Importantly, the HO system plays a vital role in a wide spectrum of physiologic including the regulation of blood vessel tone. Alterations in the activity and expression of HO has been correlated to pathophysiology of hypertension and related complications such as hypertrophy, myocardial infarction and heart failure. Moreover, the cytoprotection exerted by HO is attributable to its catabolic products namely, carbon monoxide, bilirubin/biliverdin, and ferritin that are known to modulate immune, inflammatory and oxidative insults. The growing incidence of hypertension and associated cardiometabolic complications has prompted the need for the exploration of alternative therapeutic strategies like substances capable of potentiating the HO system. This review briefly, highlights the functional significance of the HO system and its downstream signaling molecules including bilirubin/biliverdin, carbon monoxide and ferritin as potential therapeutic modalities for the management of hypertension and its related co-morbid conditions.

• Authors: Shuchita Tiwari, Joseph Fomusi Ndisang
• Journal: Current pharmaceutical design (Curr Pharm Des) Vol. 20 Issue 9 Pg. 1354-69 ( 2014) ISSN: 1873-4286 [Electronic] United Arab Emirates
• PMID: 23978093 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Carbon Monoxide
• Ferritins
• Heme Oxygenase (Decyclizing)
• Heme Oxygenase-1
• Biliverdine
• Bilirubin

Topics

• Animals
• Bilirubin (metabolism)
• Biliverdine (metabolism)
• Carbon Monoxide (metabolism)
• Ferritins (metabolism)
• Heme Oxygenase (Decyclizing) (metabolism)
• Heme Oxygenase-1 (metabolism)
• Humans
• Hypertension (complications, drug therapy, physiopathology)
• Oxidative Stress
• Signal Transduction (physiology)